The Cancer Letter
@TheCancerLetter
The leading independent source for information on the issues that shape #oncology since 1973. Editor: @PaulBGoldberg | Historical initiative: @cancerhistproj
ID:23330343
http://www.cancerletter.com 08-03-2009 17:32:44
9,6K Tweets
25,8K Followers
1,5K Following
Follow People
Carl Ola Landgren (Sylvester Comprehensive Cancer Center): 'I think we have come a long way...we never gave up. I think it’s another example of the fact that if you want to be bold & you want to do something with impact, something that is important, you have to be resilient.'
cancerletter.com/conversation-w…
.FDA Oncology's Pazdur: “Multiple myeloma is really a true picture of the success of the accelerated approval program. We have 17 drugs that—almost all of them—were approved on accelerated approval. All of them were approved on non-survival endpoints.'
cancerletter.com/regulatory-new…
Carl Ola Landgren (Sylvester Comprehensive Cancer Center): 'It takes, really, a lot of trust. It takes trust, and you have to have relationships, and you have to also have a clear path to explain to the companies how this is important.'
cancerletter.com/conversation-w…
Ray Blind named associate director for DEI at Vanderbilt-Ingram (Vanderbilt-Ingram Cancer Center).
cancerletter.com/in-brief/20240…
European Commission (European Commission) approves Xtandi for high-risk BCR nmHSPC.
cancerletter.com/drugs-and-targ…
Other factors, such as more multiple myeloma diagnoses, mistrust of the healthcare system, and lack of financial and caregiver support, may also contribute to disparities in treatment utilization, Naseem Esteghamat (UC Davis Comprehensive Cancer Cent) said.
cancerletter.com/health-equity/…
Shanda Blackmon (Shanda Blackmon, MD) named director of Baylor’s Lung Institute.
cancerletter.com/in-brief/20240…
siRNA halts ccRCC tumor growth in phase I trial (UT Southwestern Medical Center).
cancerletter.com/clinical-round…
In 2009, Carl Ola Landgren (Sylvester Comprehensive Cancer Center) noticed that nearly all of his multiple myeloma patients were responding to the state-of-the-art drugs he was giving them at the NCI clinical center in Building 10 in Bethesda.
cancerletter.com/conversation-w…
Black patients are less likely than patients of other races and ethnicities to receive autologous hematopoietic cell transplants for multiple myeloma, according to a study in the April issue of Clinical Lymphoma, Myeloma, and Leukemia. #HealthEquity
cancerletter.com/health-equity/…